JMJD2A ACTIVE HUMAN

JMJD2A ACTIVE HUMAN

Biochem/physiol Actions

JMJD2A (Jumonji domain containing 2A) acts as a repressor of transcription, and interacts with histone deacetylase complexes and Rb (retinoblastoma) protein. In histone H3, H3K9me2/3 and H3K36me2/3, this protein is responsible for the demethylation of di- and trimethylated Lys9 and Lys36 residues. It is up-regulated in breast cancer and is responsible for the transcriptional repression of the tumor suppressor ARHI (aplasia Ras homolog member I) which eventually promotes breast cancer proliferation, migration and invasion.

General description

Human JMJD2A, also known as JHDM3A and KDM4A (GenBank Accession No. NM_014663), amino-acids 1-350 with N-terminal His-tag, MW=42 kDa, expressed in an E.coli expression system.

JMJD2A (Jumonji domain containing 2A) belongs to the conserved family of Jmjc domain-containing proteins, which in turn are a part of the Jmjc domain histone demethylase superfamily. JMJD2A protein is composed of 1064 amino acids, and contains JmjN and JmjC domains in the catalytic core, a linker region of 350 residues, two plant homeodomains (PHD), and a double Tudor domain. It is one of the six JMJD2 homologs found in humans, ranging from JMJD2A to JMJD2F. It is a trimethyllysine-specific JmjC histone demethylase (HDM).

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Manufacturer Form Assay Price Quantity
3576753 JMJD2A ACTIVE HUMAN SIGMA-ALDRICH aqueous solution ≥80% (SDS-PAGE)
£820.39 (exc VAT) per EACH
-
+
3576754 JMJD2A ACTIVE HUMAN SIGMA-ALDRICH aqueous solution ≥80% (SDS-PAGE)
£764.68 (exc VAT) per 100UG
-
+